Last reviewed · How we verify
NVA237
At a glance
| Generic name | NVA237 |
|---|---|
| Also known as | glycopyrronioum bromide |
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma (PHASE2)
- A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence (PHASE3)
- Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment (PHASE1)
- A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD (PHASE4)
- Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen (PHASE4)
- Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma (PHASE2, PHASE3)
- Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (PHASE3)
- A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVA237 CI brief — competitive landscape report
- NVA237 updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI